It is worthwhile for clinicians to be alerted that high expression of CD44 & CD133 is associated with poor prognosis in early-stage patients, and patients with high expression of CD44 & CD133 do not seem to be able to derive significant survival benefit from adjuvant therapy, so these patients may need targeted therapy for tumor stemness. The gene discussed is PROM1; the disease is neoplasm.